Company Listing
Chroma

Chroma was developing therapeutics for cancer and inflammatory disorders. The company built a pipeline of potential treatments using its expertise in chromatin biology and its novel intracellular accumulation technologies that included the ability to selectively target drugs to macrophages. The company sold rights to its lead development compound, an oral, once daily experimental cancer therapy, tosedostat, to CTI BioPharma. Chroma has partnered a number of preclinical assets with GlaxoSmithKline to develop macrophage-targeted compounds.

BACK
Location
Oxford, UK
CEO
Richard Bungay
Abingworth Partner
Tim Haines
Website Address

Home

About Us

  1. About Us
  2. Our Team
  3. Transatlantic Reach
  4. Funds

Strategy

  1. Our Strategy
  2. Venture Capital
  3. Clinical Co‑development
  4. VIPEs
  5. Public Markets

Portfolio

  1. Portfolio Companies
  2. Case Studies

Media Centre

  1. Recent News
  2. Archived News
  3. Film

Contact

  1. Contact Us
  2. Send Us Your Proposal
Company Listing

Chroma was developing therapeutics for cancer and inflammatory disorders. The company built a pipeline of potential treatments using its expertise in chromatin biology and its novel intracellular accumulation technologies that included the ability to selectively target drugs to macrophages. The company sold rights to its lead development compound, an oral, once daily experimental cancer therapy, tosedostat, to CTI BioPharma. Chroma has partnered a number of preclinical assets with GlaxoSmithKline to develop macrophage-targeted compounds.

Location
Oxford, UK
CEO
Richard Bungay
Abingworth Partner
Tim Haines
Website Address
BACK
 
Copyright Abingworth 2017